Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3R1 | P27986 | 19/20 | 0.58 |
| ▸ | PIK3CA | P42336 | 19/20 | 0.58 |
| ▸ | MTOR | P42345 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12986907 | 1.00 | PIK3R1 (0.58) | PIK3R1PIK3CAMTOR | |
| SCHEMBL13195154 | 0.88 | PIK3R1 (0.52) | PIK3R1PIK3CAMTOR | |
| SCHEMBL15769161 | 0.88 | PIK3R1 (0.52) | PIK3R1PIK3CAMTOR | |
| SCHEMBL15769511 | 0.86 | MTOR (0.55) | PIK3R1PIK3CAMTOR | |
| SCHEMBL15769509 | 0.86 | MTOR (0.55) | PIK3R1PIK3CAMTOR | |
| SCHEMBL13194570 | 0.85 | MTOR (0.56) | PIK3R1PIK3CAMTOR | |
| SCHEMBL15769606 | 0.85 | MTOR (0.56) | PIK3R1PIK3CAMTOR | |
| SCHEMBL15769989 | 0.85 | MTOR (0.57) | PIK3R1PIK3CAMTOR | |
| SCHEMBL15769987 | 0.85 | MTOR (0.57) | PIK3R1PIK3CAMTOR | |
| SCHEMBL13194646 | 0.84 | MTOR (0.60) | PIK3R1PIK3CAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140163023-A1 | DIHYDROPYRROLO PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | CELLZOME LIMITED (GB) | 2014-06-12 | — | — | US | disclosed |
| US-20140163023-A1 | DIHYDROPYRROLO PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | CELLZOME LIMITED (GB) | 2014-06-12 | — | — | US | disclosed |
| US-20140163023-A1 | DIHYDROPYRROLO PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | CELLZOME LIMITED (GB) | 2014-06-12 | — | — | US | disclosed |
| EP-2694511-A1 | DIHYDROPYRROLO PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | Cellzome Limited (GB) | 2014-02-12 | — | — | EP | disclosed |
| WO-2012136622-A1 | DIHYDROPYRROLO PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | CELLZOME LIMITED (GB) | 2012-10-11 | — | — | WO | disclosed |
| WO-2012136622-A1 | DIHYDROPYRROLO PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | CELLZOME LIMITED (GB) | 2012-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163023-A1 | DIHYDROPYRROLO PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | MTOR, RICTOR, RPTOR | PIK3R1 119/4885PIK3CA 34/4885MTOR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.